Insight on Therapy Area

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

Autoimmune Market Access in China – New biologic therapies drive future growth

Despite ongoing competition from biosimilars, branded biologics will continue to drive the Chinese autoimmune market, with two new brands, Enbrel (etanercept; Pfizer) and Humira (adalimumab; Abbott), having been approved and launched in 2010.

Published By Datamonitor
14 Sep 2011 $2800
Buy
Report
Report

Autoimmune Market Access in India – Market opportunities for cost-effective biosimilars

The launch and uptake of biologics has grown across India – primarily in urban areas – but affordability is a major limiting factor, thereby providing an opportunity for the pharmaceutical companies manufacturing cost-effective biosimilars.

Published By Datamonitor
25 Aug 2011 $2800
Buy
Brief
Brief

Brief: Hepatitis C/AASLD 2010

This brief is an overview of the HCV highlights from the 2010 American Association of the Study of Liver Disease meeting. It discusses pivotal data for telaprevir and boceprevir, results for TMC435 and data from interferon-sparing studies.

Published By Datamonitor
13 Dec 2010 $400
Buy
Report
Report

Bydureon FDA Approval: Physician Opinion

Physician survey of 84 endocrinologists and primary care physicians on their impressions and expected use of Amylin’s and Alkermes’s Bydureon (once-weekly exenatide)

Published By Datamonitor
24 Feb 2012 $2800
Buy
Report
Report

Cardiovascular and Metabolic Diseases Market Access in China – Managing challenges to harness growing commercial potential

The large number of Chinese CV & metabolic diseases patients brings significant commercial opportunities for Pharma. Plans to expand insurance coverage and improve healthcare infrastructure will enhance therapy access, boosting the market potential.

Published By Datamonitor
09 Dec 2011 $2800
Buy
Report
Report

Case Study: Autism Spectrum Disorders – Public awareness and physician detailing will drive market growth

This report examines the opportunities and threats within the autism spectrum disorders (ASDs) market. The analysis is intended to support company strategy and decision-making by providing actionable recommendations in the current treatment pathway.

Published By Datamonitor
16 Apr 2012 $1520
Buy
Report
Report

Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugs

This module discusses differential pricing for antiretrovirals as a strategy that enhances access to drugs while preserving incentives for pharmaceutical companies.

Published By Datamonitor
18 May 2011 $1520
Buy
Report
Report

Case Study: Personalized Cancer Therapy - Anticipated competition threatens to dampen commercial potential of new approvals

Overview of targeted cancer therapies and biomarkers, with in-depth analysis of drug and companion diagnostic development, commercial potential, role of regulatory authorities in the seven major markets and key pipeline personalized cancer therapies.

Published By Datamonitor
16 Jul 2012 $1520
Buy
Report
Report

Case Study: Sepsis - Xigris’ disappointing performance creates a market opportunity for improved sepsis therapies

The Surviving Sepsis Campaign has created an increased focus on reducing levels of mortality from sepsis. Eli Lilly/BioCritica’s Xigris has been unable to capitalize on what remains a potentially lucrative therapy area with significant unmet needs.

Published By Datamonitor
17 May 2011 $1520
Buy
Report
Report

Central Nervous System Drug Delivery Specialists

CNS drugs are associated with longer development times and higher attrition rates than drugs for other therapy areas. Advances in delivery technologies are essential if the pursuit of novel CNS treatments is to remain commercially viable.

Published By Datamonitor
05 Sep 2012 $2800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.